AstraZeneca strategically adjusted its $1.4 billion sale of Anatrol and Bikaruan

▍1.4 billion, AstraZeneta sold two cancer drugsrecently, foreign media reported that as part of a strategic shift, AstraZeneatic sold rights to two cancer drugs in Europe, Africa and other countries to Juvis Pharmaceuticals.It is understood that the drugs Arimidex and Casodex (Picaruamine) are primarily used to treat breast and prostate cancer, and have lost patent protection in those areas, the company sold the rights to both drugs in the United States in 2017.Juvisé, a French pharmaceutical company, intends to enter the oncology market through the deal. The company had previously focused on the production and commercialization of drugs for cardiovascular, tumor and neuropsycological disorders, according to the data.The French pharmaceutical company has been selling its own drugs in 75 countries, despite its 11-year history.Juvis's Pharmaceuticals paid $181 million in advance, while future sales or compensation amounted to $17 million, or about $200 million ($1.4 billion), and last year Arimidex brought in $37 million for the countries covered by the agreement, while Casodex brought in $24 million.In response, Dave Fredrickson, executive vice president of AstraZeneca's oncology business, said: Arimidex and Casodex are important mature drugs for AstraZeneca, and the sale is part of AstraZeneca's strategy to reduce its mature drug portfolio and redistribute resources to develop new drug channels.▍ two drugs, domestic large varietiesdata show that anatrophic acid is a powerful, selective nonsteroidal aromatase inhibitor, used in post-menoptocratic women's advanced breast cancer treatment and early breast cancer auxiliary treatment. Anatrophos tablets have been used in clinical practice for many years as a Category B variety of the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (2019 edition).The original manufacturer of the variety was ANI Pharmaceutical Pharmaceuticals, which was approved for market in the United States in 1995.According to Minetrade data, in 2018 China's public medical institutions terminal anatrobe tablet sales of more than 1 billion yuan, of which AstraZeneone accounted for the largest proportion, as high as 89.72 percent.In addition to AstraZeneta, Yangzijiang Pharmaceutical Group accounted for 7.94 percent, Chongqing Huabang Pharmaceuticals for 1.62 percent, Zhejiang Haizheng Pharmaceuticals for 0.51 percent and Zhejiang Wanyan Pharmaceuticals for 0.21 percent.In 2017, AZ sold Anatron's sales rights in the U.S. and, in recent days, in other countries such as Europe and Africa, whether it will involve the Chinese market in the future remains to be seen.In the past 10 years, the incidence of prostate cancer in China has risen rapidly, with the incidence of prostate cancer reaching about 98 per 100,000 people, with an average annual growth rate of 12.07 percent.In 2018, the market for terminal prostate cancer drugs in public hospitals in key provinces and cities has reached 5 billion yuan, an increase of 18.91 percent over the previous year. The main oral drugs commonly used in clinical practice in China include abithromin tablets, pictorum tablets, fluorothamiline tablets, methylamphetamine tablets, hydroxyprogesterone tablets, hexaphenol tablets, injections including docetaxel, gosherin, quprelin, and bright propylene.In the pattern of anti-prostate cancer drugs, bicarumamine accounted for 8.21%.▍ AstraZeneta, which has been selling has been selling varieties and production pipelines frequently lately. In early December, AstraZeneca announced that it had agreed to sell Seroquel's commercial rights in the United States and Canada for $35 million to German pharmaceutical company Cheplapharm Arzneimittel, where Serrecon's patents have expired. AstraZeneta received an advance of $815 million for the asset sale. In July, AstraZeneta sold its European interest in heart failure and hypertension brand Atcand to German drugmaker Cheplapharm. In May, AstraZeneca signed a $538 million sale agreement with China Greenlee Pharmaceuticals for the mental illness drug Seroquel and slow-release tablets. In response, Mark Mallon, AstraZenecom's executive vice president of global strategy, said one of the company's strategic goals was to continue to scale down non-core therapeutic areas and invest resources in three key franchises, oncology, cardiovascular, metabolic and respiratory diseases.
(
Cypress Blue
)